Octreotide for enterocutaneous fistulas of Crohn's disease

Canadian Journal of Gastroenterology

Volumn 17, Issue 9, 2003, Pages 555-558

  Lavy, A ^a   Yasin, K ^b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Crohn's disease; Enterocutaneous fistulas; Octreotide

Indexed keywords

CIPROFLOXACIN; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OCTREOTIDE; SOMATOSTATIN;

ADOLESCENT; ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; ENTEROCUTANEOUS FISTULA; FEMALE; GALLSTONE; HUMAN; IATROGENIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE SECRETION; MALE; PANCREAS FISTULA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0142182051     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/645751     Document Type: Article

References (45)

1. Givel J, Hawker P, Allan R, et al. Entero-enteric fistulas complicating Crohn's disease. J Clin Gastroenterol 1983;5:321-3.
2. Greenstein AJ, Sachar DB, Tzakis A, Sher L, Heimann T, Aufses AH Jr. Course of enterovesical fistulas in Crohn's disease. Am J Surg 1984;147:788-92.
3. Janowitz HD. The problems of fistulas. In: Janowitz HD, ed. Inflammatory Bowel Disease. A Personal View. Chicago: Year Book Medical Publishers, 1985:105.
4. Radcliffe AG, Ritchie JK, Hawley PR, Lennard-Jones JE, Northover JMA. Anovaginal and rectovaginal fistulas in Crohn's disease. Dis Colon Rectum 1988;31:94-9.
5. Greenstein AJ, Kark AE, Dreiling DA. Crohn's disease of the colon. I. Fistula in Crohn's disease of the colon, classification presenting features and management in 63 patients. Am J Gastroenterol 1974;62:419-29.
6. Kornbluth A, Sachar DB, Salomon P. Crohn's disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal and Liver Disease, 6th ed. Philadelphia: Saunders, 1998:1715.
7. Wilton PB, Goldberg SM. Perianal disease. In: Bayless TM, ed. Current Managment of Inflammatory Bowel Disease. Philadelphia: BC Decker, 1989:298.
8. Sohn N, Korelitz BI, Weinstein MA. Anorectal Crohn's disease. Definitive surgery for fistulas and recurrent abscess. Am J Surg 1980;139;394-7.
9. Korelitz BI, Present DH. Favorable effects of 6 mercaptopurine in fistulae of Crohn's disease. Dig Dis Sci 1985;30:58-64.
10. Present DH, Korelitz BI, Wische M, et al. Treatment of Crohn's disease with 6MP. A long term randomized double-blind study. N Eng J Med 1980;302:981-7.
11. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistula. Am J Gastro 1984;79:533-40.
12. Lichtiger S, Present DH. Cyclosporine therapy in the treatment of Crohn's perianal fistulous disease. J Autoimmunol 1991;2:A29. (Abst)
13. Smith MB, Hanauer SB. Rapid closure of Crohn's disease fistulae with intravenous cyclosporin A (CyA). Am J Gastroenterol 1991;86:1376. (Abst)
14. Present DH. Crohn's fistula: Current concepts in management. Gastroenterology 2003;124:1629-35.
15. Present DH, Rutgeerts P, Taragan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Eng J Med 1999;340:1398-405.
16. Calam J, Gatei MA, Domin J, et al. Regional differences in concentrations of regulatory peptides in human colon mucosal biopsy. Dig Dis Sci 1989;34:1193-8.
17. Mayer EA, Raybould H, Koelbel C. Neuropeptides, inflammation, and motility. Dig Dis Sci 1988;33:71S-7S.
18. Dawson J, Bryant MG, Bloom SR, Peters TJ. Gastrointestinal regulatory peptide storage granule abnormalities in jejunal mucosal diseases. Gut 1984;25:636-43.
19. Blum AM, Elliot DE, Metwali A, Li J, Qadir K, Weinstock JV. Substance P regulates Somatostatin expression in inflammation. J Immunol 1998;161:6316-22.
20. Reubi JC, Laissue J, Waser B, Horisberger U, Sacher JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic gastrointestinal tissues. Ann NY Acad Sci 1994;33:122-37.
21. Guandalini S, Kachur JF, Smith PL, Miller RJ, Field M. In vitro effects of somatostatin on ion transport in rabbit intestine. Am J Physiol 1980;38:G67.
22. Dharmsathaphorn K, Racusen L, Dobbins JW. Effects of somatostatin on ion transport in the rat colon. J Clin Invest 1980;66:813-20.
23. Dharmasathaphorn K, Sherwin RS, Dobbins JW .Somatostatin inhibits fluid secretion in the rat jejunum. Gastroenterology 1980;78:1554-8.
24. Kvols LK, Moertel CG, O'Connel MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue. N Eng J Med 1986;315:663.
25. Maton PN, O'Dorisio TM, Howe BA, et al. Effects of a long acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Eng J Med 1985; 312:17.
26. Harris AG. Octreotide in the treatment of the gastrointestinal tract. Drug Invest 1992;4:1-54.
27. Acromegaly Therapy Consensus Development Panel. Benefits versus risks of medical therapy for acromegaly. Am J Med 1994;97:468-73.
28. Chanson P, Weintraub BD, Harris AG. Octereotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas: A follow-up of 52 patients. Ann Intern Med 1993;119:236-40.
29. Krulich L, Dhariwal APS, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968;83:783-90.
30. Farthing MJG. Octreotide in the treatment of refractory diarrhea and intestinal fistulas. Gut Suppl 1994;3:S5-10.
31. Lamberts SWJ, Van der Lely AJ, De Herder WW, Hofland LJ. Octreotide. N Eng J Med 1996;334:246-54.
32. Buchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 1992;163:125-31.
33. Bassi C, Falconi M, Lombardi D, et al. Prophylaxis of complications after pancreatic surgery: Results of a multicenter trial in Italy. Digestion 1994;55(Suppl 1):41-7.
34. Patel YC. General aspects of the biology and function of somatostatin. In: Basic Clinical Aspects of Neuroscience, Vol 4. Heidelberg, Germany: Springer-Verlag, 1992. {Editors?}
35. Reubi JC, Waser B, Horisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 1992;82:2143-51.
36. Scott NA, Finnegan S, Irving MH. Octreotide and gastrointestinal fistulae. Digestion 1990;45(Suppl):66-71.
37. Sitges-Serra A, Guirao X, Pereira JA, Nubiola P. Treatment of gastrointestinal fistulas with Sandostatin. Digestion 1993;54(Suppl):38-40.
38. Borison DI, Bloom AD, Pritchard TJ. Treatment of enterocutaneous and colocutaneous fistulas with early surgery or somatostatin analog. Dis Colon Rectum 1992;35:635-9.
39. Torres AJ, Landa JI, Moreno-Azcoita M, Somatostatin in the management of gastrointestinal fistulas. Arch Surg 1992;127:97-100.
40. Skvarilova M, Nicakova R, Axmann K. New alternatives for the treatment of fistulas in Crohn's disease. Acta Univ. Palacki Fac Med 1994;138P:29-31.
41. Jabri B, Babyyatsky M, Somatostatin receptors are expressed by intraepithelial lymphocytes and regulate T-cell activation. Gastroenterol 2000;118:A791.
42. Weinstock JV, Elliot D. The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur J Endocrinol 2000;143:S15-9.
43. Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999;29:2454-63.
44. Patel T, Ping J, Sheharyar A, Babyatsky MW. Regulation of chemocytokines by somatostatin in human colonic epithelial cell line. Gastroenterol 2000;118:A93.
45. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40.